Join our daily newsletter At The Bell to receive exclusive market insights
- Uscom (UCM) has created two specialised cardiovascular monitors for sale in China
- The USCOM O2 and USCOM Basic round out the Australian company’s three-tier range of haemodynamic monitors
- UCM must first obtain regulatory approval from the Chinese National Medical Products Administration (NMPA) before commencing sales
- Its existing USCOM 1A device is used to diagnose and monitor conditions such as sepsis, heart failure and hypertension
- To date, the company has sold upwards of 500 USCOM 1A devices in China, with the product recommended for managing serious COVID-19 cases
- Meanwhile, the NMPA has approved the sale of UCM’s BP+ hypertension monitor in China, with sales revenue expected within three months
- Company shares last traded at 15.5 cents each
Medical technology developer Uscom (UCM) has created two specialised cardiovascular monitors for sale in China.
The USCOM O2 and USCOM Basic round out the Australian company’s three-tier range of haemodynamic monitors.
Firstly, however, UCM must obtain regulatory approval from the Chinese National Medical Products Administration (NMPA) prior to commencing sales.
The nine-step approval process includes document writing, collection, translation, review and product testing, and is estimated to take 12 months.
The company’s existing device, the USCOM 1A, is an advanced haemodynamic monitor, which can be used to diagnose and manage sepsis, heart failure and hypertension as well as administer fluids, inotropes and vasoactives in adults, children and neonates.
The new USCOM O2 device falls at the high end of the technology range and provides direct measurement of blood oxygen saturation to generate beat-to-beat measures of oxygen delivery.
In contrast, the USCOM Basic is a de-featured device, which the company intends to market competitively against lower-functioning technologies in price sensitive tenders.
To date, Uscom has sold more than 500 USCOM 1A units into China, with its Beijing subsidiary Uscom China generating roughly 70 per cent of the company’s global sales.
In fact, the National Health and Medical Commission of the People’s Republic of China recommends the monitor as a preferred method for managing serious COVID-19 cases.
Uscom Executive Chairman Associate Professor Rob Phillips commented on the product expansion.
“More devices equals more revenue and additional devices for sale in China, our major market, is the logical strategic next step to promote strong, ongoing revenue growth,” he said.
“These new devices will expand the market reach of our successful USCOM 1A by creating a three-tiered range of haemodynamic monitoring technologies, each with specialised features for different levels of clinical complexity and price.”
Meanwhile, Uscom recently received NMPA approval for the sale of its advanced hypertension monitoring device, the BP+ supraslystolic oscillometric BP monitor into China.
UCM is preparing the technology for market and expects to generate revenue within the next three months.
Company shares are in the grey, last trading at 15.5 cents at 4:25 pm AEST.
